Update on diabetic foot infections;Aggiornamenti in tema di infezioni del piede diabetico

Infezioni in Medicina

Volumn 20, Issue 3, 2012, Pages 155-168

  Pascale, Renato ^a   Vitale, Mario ^a   Esposito, Silvano ^a   Noviello, Silvana ^a  

^a UNIVERSITY OF SALERNO   (Italy)

Author keywords

Antibiotic therapy; Diabetic foot infection; MRSA

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; DIABETIC FOOT; FOOT DISEASE; FOOT INFECTION; HUMAN; INFECTION; MICROBIOLOGY; REVIEW;

AMPUTATION; ANTI-BACTERIAL AGENTS; DEBRIDEMENT; DIABETES COMPLICATIONS; DIABETIC FOOT; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; ITALY; PATIENT CARE TEAM; RECURRENCE; SEVERITY OF ILLNESS INDEX; THERAPEUTIC IRRIGATION; TIME FACTORS; TREATMENT OUTCOME; WORLD HEALTH; WOUND HEALING;

EID: 84866919917     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. WHO: World Health Organization. http://www.euro.who.int/en/what-we-do/healthtopics/noncommunicable-diseases/diabetes.
2. Apelqvist J., Bakker K., van Houtum W.H., Schaper N.C. International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab. Res. Rev. 24 (Suppl. 1), 181-187, 2008.
3. Prompers L., Huijberts M., Apelqvist J. et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 50, 18-25, 2007.
4. Boyko E.J., Ahroni J.H., Cohen V., Nelson K.M., Heagerty P.J., Prediction of diabetic ulcer occurrence using commonly available clinical information. The Seattle Diabetic Foot Study. Diabetes Care 29, 1202-1207, 2006.
5. Caravaggi C., Piaggesi A., Menichetti F. Diabetic foot infections. Infezioni in Medicina 17, (Suppl. 4), 77-87, 2009.
6. Repine J.E., Clawson C.C., Goetz F.E. Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetes. J. Infect. Dis. 142, 869-872, 1980.
7. Powlson A.S., Coll A.P. The treatment of diabetic foot infections. J. Antimicrob. Chemother. 65 (Suppl. 3), 3-9, 2010.
8. Lipsky B.A. Medical treatment of diabetic foot infections. Clin. Infect. Dis. 1; 39 (Suppl. 2), 104-114, 2004.
9. Eneroth M., Larsson J., Apelqvist J. Foot infections in diabetes mellitus - entity with different characteristics, treatment and prognosis. J. Diabetes Complicat. 13, 5-6, 254-263, 1999.
10. Lipsky B.A., Berendt A.R., Embil J., de Lalla F., Diagnosing and treating diabetic foot infections. Diabetes Metab. Res. Rev. 20, S56-S64, 2004.
11. Lipsky B.A., Tabak Y.P., Johannes R.S. et al. Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost. Diabetologia 53, 914-923, 2010.
12. Lipsky B.A., Berendt A.R., Cornia P.B. et al. 2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin. Infect. Dis. 54, 12, 132-173, 2012.
13. Chakraborti C., Le C., Yanofsky A. Sensitivity of superficial cultures in lower extremity wounds. J. Hosp. Med. 5, 415-420, 2010.
14. Citron D.M., Goldstein E.J., Merriam C.V., Lipsky B.A., Abramson M.A. Bacteriology of Moderate-to-Severe Diabetic Foot Infections and In Vitro Activity of Antimicrobial Agents. J. Clin. Microbiol. 45, 2819-2828, 2007.
15. Yates C.J., May K., Hale T. et al. Wound chronicity, inpatient care and chronic kidney disease predispose to MRSA infection in diabetic foot ulcers. Diabetes Care 32, 1907-1909, 2009.
16. Sotto A., Richard J.L., Combescure C. et al. Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers. Diabetologia 53, 2249-2255, 2010.
17. Hoiby N., Bjarnsholt T., Givskov M. et al. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35, 322-332, 2010.
18. Otto M. Staphylococcal Infections: Mechanisms of Biofilm Maturation and Detachment as Critical Determinants of Pathogenicity. Annu. Rev. Med. 2012 Aug 16. [Epub ahead of print].
19. Joseph W.S., Lipsky B.A. Medical therapy of diabetic foot infections. J. Vasc. Surg. 52, 3 (Suppl), 67S-71S, 2010.
20. Eleftheriadou I., Tentolouris N., Argiana V., Jude E., Boulton A.J. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 70, 1785-1797, 2010.
21. Dang C.N., Prasad Y.D., Boulton A.J., Jude E.B. Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet. Med. 20, 159-161, 2003.
22. Altrichter Loan C., Legout L., Assal M., Rohner P., Hoffmeyer P., Bernard L. Infections sévères à Streptococcus agalactiae du pied diabétique. Rôle délétère du Streptococcus agalactiae? Presse Med. 34, 491-494, 2005.
23. Lipsky B.A., Armstrong D.G., Citron D.M., Tice A.D., Morgenstern D.E., Abramson M.A. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 366, 1695-1703, 2005.
24. Grayson M.L. Diabetic foot infections: antimicrobial therapy. Infect. Dis. Clin. North. Am. 9, 143-161, 1995.
25. Caputo G.M., Joshi N., Weitekamp M.R. Foot infections in patients with diabetes. Am. Fam. Physician 56, 195-202, 1997.
26. Dowd S.E., Sun Y., Secor P.R., Rhoads D.D., Wolcott B.M., James G.A. et al. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. BMC Microbiol. 8, 43, 2008.
27. Esposito S., Leone S., Noviello S., et al. Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey. Diabet. Med. 25, 8, 979-984, 2008.
28. Mlinariæ -Missoni E., Kaleniæ S., Milán V., de Syo D., Belicza M., Vaziæ-Babiæ V. Candida infections in diabetic foot ulcers. Diabetologia Croatica 34, 29-35, 2005.
29. Nair S., Peter S., Sasidharan A., Sistla S., Kochugovindan A.K. Incidence of mycotic infections in diabetic foot tissue. Journal of Culture Collections. 5, 85-89, 2007.
30. Esposito S., Leone S. Antimicrobial treatment for Intensive Care Unit (ICU) infections including the role of the infectious disease specialist. Int. J. Antimicrob. Agents 29, 5, 494-500, 2007.
31. Ramakant P., Verma A.K., Misra R., et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose? Diabetologia 54, 58-64, 2011.
32. Lipsky B.A. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin. Microbiol. Infect. 13, 351-353, 2007.
33. Lipsky B.A., Peters E.J., Senneville E. et al. Expert opinion on the management of infections in the diabetic foot. Diabetes Metab. Res. Rev. 28, 1,163-178, 2012.
34. Marangos M.N., Skoutelis A.T., Nightingale C.H. et al. Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother. 39, 9, 2161-2163, 1995.
35. Lipsky B.A., Holroyd K.J., Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin. Infect. Dis. 47, 12, 1537-1545, 2008.
36. Lipsky B.A., Kuss M., Edmonds M. et al. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J. Am. Podiatr. Med. Assoc.102, 3, 223-232, 2012.
37. Dawis M.A., Isenberg H.D., France K.A. et al. In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug- resistant organisms. J. Antimicrob. Chemother. 51, 1203, 2003.
38. Gould I.M., David M.Z., Esposito S. et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents. 39, 2, 96-104, 2012.
39. Dryden M., Andrasevic A.T., Bassetti M., Bouza E., Chastre J., Cornaglia G., Esposito S., French G., Giamarellou H., Gyssens I.C., Nathwani D., Unal S., Voss A. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin. Microbiol. Infect. 16, 3-30, 2010.
40. Gould I.M., Cauda R., Esposito S. et al. Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? Int. J. Antimicrob. Agents, 37, 202-209, 2011.
41. Roberts A.D., Simon G.L. Diabetic foot infections: the role of microbiology and antibiotic treatment. Semin. Vasc. Surg. 25, 2, 75-81, 2012.
42. Mruk A.L., Record K.E. Antimicrobial options in the treatment of adult staphylococcal bone and joint infections in an era of drug shortages. Orthopedics. 35, 401-407, 2012.
43. Calvo J., Martinez L. Mecanismo de accion de los antimicrobianos. Enferm. Infecc. Microbiol. Clin. 27, 44-52, 2009.
44. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering R.C. Jr, Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 398-402, 2004
45. Lodise T.P., Lomaestro B., Graves J., Drusano G.L. Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity. Antimicrob. Agents Chemother. 52, 1330-1336, 2008
46. Soriano A., Marco F., Martínez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46, 193-200, 2008.
47. Hawser S.P., Bouchillon S.K., Hoban D.J. et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int. J. Antimicrob. Agents. 37, 219-224, 2011.
48. Kosinski M.A., Lipsky B.A. Current medical management of diabetic foot infections. Expert. Rev. Anti. Infect. Ther. 8, 1293-305, 2010
49. Sievert D.M., Rudrik J.T., Patel J.B. et al. Vancomycin- resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46, 668-674, 2008.
50. Finks J., Wells E., Dyke T.L., et al. Vancomycin resistant Staphylococcus aureus, Michigan, USA 2007. Emerg. Infect. Dis. 15, 943-945, 2009.
51. Saha B., Singh A.K., Ghosh A., Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J. Med. Microbiol. 57, 72-79, 2008.
52. Aligholi M., Emaneini M., Jabalameli F., et al. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med. Princ. Pract. 17, 432-434, 2008.
53. Sader H.S., Watters A.A., Fritsche T.R., Jones R.N. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin- resistant enterococci isolated in European medical centers. BMC Infect. Dis. 18, 7, 29, 2007.
54. Mascio C.T.M., Alder J.D., Silverman J.A. Bactericidal Action of Daptomycin against Stationary- Phase and Nondividing Staphylococcus aureus Cells. Antimicrob. Agents Chemother. 51, 255-260, 2007.
55. Traunmuller F., Schintler M.V., Metzler J., et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. 65, 1252-1257, 2010.
56. Johnson K., Lamp K.C., Friedrich L.V. Retrospective review of the use of daptomycin for diabetic foot infections. J. Wound Care 18, 396-400, 2009.
57. Novartis. Cubicin. Summary of product characteristics. Novartis; 2006.
58. Seaton R.A., Daptomycin: rationale and role in the management of skin and soft tissue infections. J. Antimicrob. Chemother. 62, 1 5-23, 2008.
59. Liu C., Bayer A., Cosgrove S.E. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52, 18-55, 2011.
60. Moise P.A., Hershberger E., Amodio-Groton M.I. et al. Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy. Ann. Pharmacother. 43, 1211-1219, 2009.
61. Utili R., Dohmen P., Dailiana Z., et al. Evaluation of safety and tolerability of daptomycin doses ≥8 mg/kg/day: results from 270 patients in the European Cubicin® Outcomes Registry and Experience (EU-COREsm). In: 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/27th International Congress on Chemotherapy (ICC). 2011 [Abstract P1538].
62. Bassetti M., Nicco E., Ginocchio F. et al. Highdose daptomycin in documented Staphylococcus aureus infections. Int. J. Antimicrob. Agents 36, 459-461, 2010.
63. Figueroa D.A., Mangini E., Amodio-Groton M., et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin. Infect. Dis. 49, 177-180, 2009.
64. Majcher-Peszynska J., Haase G., Sass M., et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur. J. Clin. Pharmacol. 64, 1093-1100, 2008.
65. Brier M.E., Stalker D.J., Aronoff G.R., et al. Pharmacokinetics of Linezolid in subjects with renal dysfunction. Antimicrob. Agents. Chemother. 47, 775-780, 2003.
66. Matsumoto K., Takeshita A., Ikawa K. et al. Higher Linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int. J. Antimicrob. Agents 36, 179-181, 2010.
67. Nambiar S., Rellosa N., Wassel R.T. et al. Linezolid- associated peripheral and optic neuropathy in children. Pediatrics 127, 6, 1528-1532, 2011.
68. Beibei L., Yun C., Mengli C., et al. Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents 35, 3-12, 2010.
69. Dodds T.J., Hawke C.I. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ. J. Surg. 79, 629-635, 2009.
70. Bounthavong M., Hsu D.I. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr. Med. Res. Opin. 26, 407-421, 2010.
71. Logman J.F., Stephens J., Heeg B., et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr. Med. Res. Opin. 26, 1565-1578, 2010.
72. Itani K.M., Dryden M.S., Bhattacharyya H., Kunkel M.J., Baruch A.M., Weigelt J.A. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. 199, 804-816, 2010.
73. Gold H.S., Satish K.P. Antistaphylococcal agents. Infect. Dis. Clin. N. Am. 23, 99-131, 2009.
74. Eckmann C., Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur. J. Med. Res. 15, 12, 554-563, 2010.
75. Nicolau D.P. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert. Opin. Pharmacother. 10, 1213-1222, 2009
76. Ellis-Grosse E.G., Babinchak T., Dartois N., et al. The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double- blind phase 3 comparison studies with vancomycin- aztreonam. Clin. Infect. Dis. 41, 341-353, 2005.
77. Petersen P.J., Ruzin A., Tuckman M., et al. In vitro activity of tigecycline against patient isolates col lected during phase 3 clinical trials for diabetic foot infections. Diagn. Microbiol. Infect. Dis. 66, 407-418, 2010.
78. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18, 657-686, 2005.
79. Livermore D.M., Sefton A.M., Scott G.M. Properties and potencial of ertapenem. J. Antimicrob. Agents 52, 331-344, 2003.
80. Shklyar A., Miller E.B., Landau Z. Efficacy of Ertapenem for Secondary Treatment of Diabetic Foot Infections. Wounds 22, 158-160, 2010.
81. Bassetti M., Righi E., Esposito S., Petrosillo N., Nicolini L. Drug treatment for multidrug-resistant Acinetobacter baumannii infections. Future Microbiol. 3, 6, 649-660, 2008.
82. Tascini C., Gemignani G., Palumbo F., et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J. Chemother. 18, 648-651, 2006.
83. Graham D.R., Lucasti C., Malafaia O., et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin. Infect. Dis. 34, 1460-1468, 2002.
84. Ertugrul M.B., Baktiroglu S., Salman S., et al. Pathogens isolated from deep soft tissue and bone in patients with diabetic foot infections. J. Am. Podiatr. Med. Assoc. 98, 290-295, 2008.
85. Martinez-Gomez Dde A., Ramirez-Almagro C., Campillo-Soto A., Morales-Cuenca G., Pagan-Ortiz J., Aguayo-Albasini J.L. Diabetic foot infections. Prevalence and antibiotic sensitivity of the causative microorganisms. Enferm. Infecc. Microbiol. Clin. 27, 317-321, 2009.
86. Bansal E., Garg A., Bhatia S., Attri A.K., Chander J. Spectrum of microbial flora in diabetic foot ulcers. Indian J. Pathol. Microbiol. 51, 204-208, 2008.
87. Yoga R., Khairul A., Sunita K., Suresh C. Bacteriology of diabetic foot lesions. Med. J. Malaysia 61, 14-6, 2006.
88. Berendt A.R., Peters E.J., Bakker K., et al. Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment. Diabetes Metab. Res. Rev. 24, 145-161, 2008.
89. Senneville E., Lombart A., Beltrand E., et al. Outcome of diabetic foot osteomyelitis treated nonsurgically: a retrospective cohort study. Diabetes Care 31, 637-642, 2008.
90. Esposito S., Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int. J. Antimicrob. Agents. 32, 4, 287-293, 2008.
91. J.I.; Representatives of Spanish Society of Surgeons (ACS); Representatives of Spanish Society of Angiology and Vascular Surgery (SEACV); Representatives of Spanish Society of Emergency Medicine (SEMES); Spanish Internal Medicine Society (SEMI); Representatives of Spanish Society of Critical Care Medicine and Coronary Units (SEMICYUC); Representatives of Spanish Society of Chemotherapy (SEQ). Consensus document on treatment of infections in diabetic foot. Rev. Esp. Quimioter. 24, 233-262, 2011.
92. Petronella P., Scorzelli M., Fiore A., Corbisiero M.C., Agresti E., Esposito S., Freda F. Antibiotic prophylaxis in catheter-associated urinary infections. New Microbiol. 35, 2, 191-198, 2012.
93. Esposito S., Esposito I., Leone S. Considerations of antibiotic therapy duration in community- and hospital-acquired bacterial infections. J. Antimicrob. Chemother. 2012 Jul 24. [Epub ahead of print]
94. Rice L.B. The Maxwell Finland Lecture: For the duration - rational antibiotic administration in an era of antimicrobial resistance and Clostridium difficile. Clin. Infect. Dis. 46, 491-496, 2008.
95. Marvaso A., Esposito S., Noviello S., et al. Outpatient Parenteral Antibiotic Therapy (OPAT) of diabetic foot infections with piperacillin/tazobactam. Infezioni in Medicina 10, 230-235, 2002.
96. Lipsky B.A., Pecoraro R.E., Larson S.A., Hanley M.E., Ahroni J.H. Outpatient management of uncomplicated lower-extremity infections in diabetic patients. Arch. Intern. Med. 150, 790-797, 1990.
97. Esposito S., Leone S., Noviello S., et al. Outpatient parenteral antibiotic therapy for bone and joint infections: an italian multicenter study. J. Chemother. 19, 4, 417-422, 2007.